 Allen Cohn
Concepts (195)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 25 | 2024 | 848 | 2.500 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 31 | 2021 | 1958 | 2.090 |
Why?
| | Antibodies, Monoclonal, Humanized | 27 | 2024 | 988 | 1.570 |
Why?
| | ras Proteins | 7 | 2019 | 151 | 1.520 |
Why?
| | Phenylurea Compounds | 10 | 2024 | 112 | 1.250 |
Why?
| | Antibodies, Monoclonal | 16 | 2018 | 1524 | 1.240 |
Why?
| | Adenocarcinoma | 9 | 2016 | 931 | 1.010 |
Why?
| | Proto-Oncogene Proteins | 5 | 2015 | 623 | 0.740 |
Why?
| | Fluorouracil | 17 | 2019 | 235 | 0.730 |
Why?
| | Camptothecin | 12 | 2019 | 140 | 0.670 |
Why?
| | Liver Neoplasms | 6 | 2026 | 783 | 0.670 |
Why?
| | Leucovorin | 14 | 2019 | 101 | 0.670 |
Why?
| | Quinolines | 5 | 2024 | 193 | 0.650 |
Why?
| | Organoplatinum Compounds | 14 | 2017 | 66 | 0.640 |
Why?
| | Disease-Free Survival | 14 | 2017 | 769 | 0.620 |
Why?
| | Bevacizumab | 15 | 2024 | 167 | 0.600 |
Why?
| | Endometrial Neoplasms | 4 | 2024 | 208 | 0.580 |
Why?
| | Biological Therapy | 1 | 2018 | 28 | 0.540 |
Why?
| | Neoplasms | 6 | 2026 | 2884 | 0.520 |
Why?
| | Protein Kinase Inhibitors | 9 | 2025 | 970 | 0.490 |
Why?
| | Mutation | 5 | 2020 | 4099 | 0.490 |
Why?
| | Biomarkers, Tumor | 9 | 2024 | 1322 | 0.470 |
Why?
| | Antineoplastic Agents | 6 | 2025 | 2197 | 0.470 |
Why?
| | Aged | 42 | 2026 | 25947 | 0.440 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2017 | 220 | 0.440 |
Why?
| | Antimetabolites, Antineoplastic | 4 | 2009 | 105 | 0.420 |
Why?
| | Kaplan-Meier Estimate | 12 | 2018 | 966 | 0.420 |
Why?
| | Salvage Therapy | 2 | 2015 | 162 | 0.410 |
Why?
| | Carcinoma, Hepatocellular | 3 | 2017 | 372 | 0.400 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2014 | 178 | 0.390 |
Why?
| | Saccharomyces cerevisiae | 1 | 2018 | 579 | 0.390 |
Why?
| | Neoplasm Metastasis | 10 | 2019 | 695 | 0.380 |
Why?
| | Gene Expression | 1 | 2018 | 1490 | 0.380 |
Why?
| | Antineoplastic Agents, Immunological | 3 | 2021 | 199 | 0.380 |
Why?
| | Aged, 80 and over | 23 | 2018 | 8279 | 0.380 |
Why?
| | Middle Aged | 43 | 2026 | 35928 | 0.370 |
Why?
| | Giant Cell Tumor of Tendon Sheath | 2 | 2022 | 8 | 0.360 |
Why?
| | Pyrimidines | 5 | 2025 | 533 | 0.360 |
Why?
| | Cholangiocarcinoma | 2 | 2025 | 106 | 0.350 |
Why?
| | Bile Duct Neoplasms | 2 | 2025 | 128 | 0.350 |
Why?
| | Cetuximab | 7 | 2019 | 111 | 0.320 |
Why?
| | Adult | 39 | 2025 | 40506 | 0.310 |
Why?
| | Pyridines | 3 | 2018 | 605 | 0.300 |
Why?
| | Receptor, Macrophage Colony-Stimulating Factor | 2 | 2022 | 11 | 0.300 |
Why?
| | Glutamates | 2 | 2013 | 66 | 0.290 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 5 | 2015 | 253 | 0.290 |
Why?
| | Double-Blind Method | 8 | 2018 | 2029 | 0.290 |
Why?
| | Guanine | 2 | 2013 | 87 | 0.290 |
Why?
| | Antineoplastic Agents, Phytogenic | 2 | 2007 | 177 | 0.290 |
Why?
| | Carcinoma, Renal Cell | 2 | 2021 | 234 | 0.280 |
Why?
| | Female | 46 | 2026 | 78376 | 0.270 |
Why?
| | Pyrroles | 2 | 2021 | 218 | 0.260 |
Why?
| | Male | 43 | 2026 | 72406 | 0.260 |
Why?
| | Stomach Neoplasms | 3 | 2016 | 128 | 0.250 |
Why?
| | Kidney Neoplasms | 2 | 2021 | 412 | 0.250 |
Why?
| | Carcinoma, Acinar Cell | 1 | 2026 | 4 | 0.240 |
Why?
| | Paclitaxel | 1 | 2007 | 256 | 0.230 |
Why?
| | Yttrium Radioisotopes | 1 | 2026 | 64 | 0.230 |
Why?
| | Humans | 55 | 2026 | 144957 | 0.230 |
Why?
| | Circulating Tumor DNA | 1 | 2026 | 44 | 0.230 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2018 | 1141 | 0.230 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 3 | 2018 | 257 | 0.220 |
Why?
| | Treatment Outcome | 18 | 2026 | 11695 | 0.220 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 2 | 2 | 2025 | 28 | 0.220 |
Why?
| | Pancreatic Neoplasms | 3 | 2026 | 927 | 0.220 |
Why?
| | Neoplasm Staging | 7 | 2015 | 1465 | 0.210 |
Why?
| | Angiogenesis Inhibitors | 3 | 2014 | 237 | 0.200 |
Why?
| | Deoxycytidine | 6 | 2020 | 221 | 0.200 |
Why?
| | Early Detection of Cancer | 2 | 2026 | 466 | 0.200 |
Why?
| | Dose-Response Relationship, Drug | 6 | 2015 | 2032 | 0.190 |
Why?
| | Rectal Neoplasms | 1 | 2024 | 158 | 0.180 |
Why?
| | Disease Progression | 10 | 2021 | 2852 | 0.180 |
Why?
| | Cell-Free Nucleic Acids | 1 | 2022 | 33 | 0.180 |
Why?
| | Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2022 | 16 | 0.180 |
Why?
| | Drug Administration Schedule | 5 | 2014 | 783 | 0.180 |
Why?
| | Colonic Neoplasms | 1 | 2024 | 260 | 0.170 |
Why?
| | Survival Rate | 5 | 2019 | 2092 | 0.170 |
Why?
| | Esophageal Neoplasms | 2 | 2016 | 349 | 0.160 |
Why?
| | Neovascularization, Pathologic | 2 | 2019 | 286 | 0.160 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2018 | 1462 | 0.160 |
Why?
| | Niacinamide | 2 | 2017 | 86 | 0.150 |
Why?
| | Aminopyridines | 2 | 2021 | 127 | 0.150 |
Why?
| | Proto-Oncogene Proteins c-raf | 1 | 2019 | 45 | 0.150 |
Why?
| | Vascular Endothelial Growth Factor D | 1 | 2018 | 13 | 0.140 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2020 | 211 | 0.140 |
Why?
| | Immunity | 1 | 2018 | 139 | 0.130 |
Why?
| | Esophagogastric Junction | 2 | 2016 | 56 | 0.130 |
Why?
| | Anilides | 1 | 2017 | 84 | 0.120 |
Why?
| | Gonanes | 1 | 2016 | 28 | 0.120 |
Why?
| | Proportional Hazards Models | 3 | 2014 | 1325 | 0.120 |
Why?
| | Giant Cell Tumors | 1 | 2015 | 4 | 0.120 |
Why?
| | Complement Activation | 1 | 2018 | 411 | 0.110 |
Why?
| | Pyrazoles | 1 | 2018 | 510 | 0.110 |
Why?
| | Soft Tissue Neoplasms | 1 | 2015 | 127 | 0.100 |
Why?
| | Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2013 | 31 | 0.100 |
Why?
| | Insulin-Like Growth Factor Binding Proteins | 1 | 2013 | 26 | 0.100 |
Why?
| | Topoisomerase I Inhibitors | 1 | 2012 | 19 | 0.100 |
Why?
| | Receptors, IgG | 1 | 2013 | 76 | 0.100 |
Why?
| | Cisplatin | 2 | 2020 | 334 | 0.090 |
Why?
| | Heterocyclic Compounds, 4 or More Rings | 1 | 2012 | 23 | 0.090 |
Why?
| | Pemetrexed | 2 | 2013 | 38 | 0.090 |
Why?
| | Time Factors | 6 | 2021 | 7183 | 0.090 |
Why?
| | ErbB Receptors | 2 | 2015 | 629 | 0.090 |
Why?
| | Follow-Up Studies | 4 | 2019 | 5417 | 0.090 |
Why?
| | Neoplasm Proteins | 1 | 2014 | 444 | 0.090 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2021 | 557 | 0.080 |
Why?
| | Treatment Failure | 2 | 2013 | 365 | 0.080 |
Why?
| | DNA, Neoplasm | 1 | 2011 | 164 | 0.080 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2011 | 341 | 0.080 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2025 | 883 | 0.070 |
Why?
| | Capecitabine | 4 | 2013 | 57 | 0.070 |
Why?
| | Carmustine | 1 | 2008 | 52 | 0.070 |
Why?
| | Genotype | 1 | 2013 | 1835 | 0.070 |
Why?
| | Azacitidine | 1 | 2009 | 157 | 0.070 |
Why?
| | Tumor Burden | 2 | 2022 | 322 | 0.070 |
Why?
| | Prognosis | 3 | 2026 | 4293 | 0.070 |
Why?
| | Polyethylene Glycols | 1 | 2012 | 655 | 0.070 |
Why?
| | Blood Cell Count | 1 | 2007 | 54 | 0.060 |
Why?
| | Cohort Studies | 3 | 2014 | 5965 | 0.060 |
Why?
| | Vitamin B 12 | 1 | 2008 | 127 | 0.060 |
Why?
| | Half-Life | 1 | 2007 | 151 | 0.060 |
Why?
| | Myelodysplastic Syndromes | 1 | 2009 | 147 | 0.060 |
Why?
| | Area Under Curve | 1 | 2007 | 331 | 0.060 |
Why?
| | Folic Acid | 1 | 2008 | 199 | 0.060 |
Why?
| | Adolescent | 6 | 2024 | 22453 | 0.060 |
Why?
| | Dexamethasone | 1 | 2008 | 372 | 0.060 |
Why?
| | Pancreaticoduodenectomy | 1 | 2026 | 135 | 0.050 |
Why?
| | Carcinoma | 1 | 2006 | 228 | 0.050 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2013 | 1182 | 0.050 |
Why?
| | Glioma | 1 | 2008 | 426 | 0.050 |
Why?
| | Young Adult | 4 | 2014 | 14126 | 0.050 |
Why?
| | Taxoids | 2 | 2013 | 116 | 0.050 |
Why?
| | Longitudinal Studies | 2 | 2026 | 2947 | 0.050 |
Why?
| | Apoptosis | 1 | 2011 | 2430 | 0.050 |
Why?
| | Cytarabine | 1 | 2002 | 66 | 0.040 |
Why?
| | United States | 5 | 2021 | 15988 | 0.040 |
Why?
| | Response Evaluation Criteria in Solid Tumors | 1 | 2022 | 21 | 0.040 |
Why?
| | Prospective Studies | 2 | 2012 | 7997 | 0.040 |
Why?
| | Meningeal Neoplasms | 1 | 2002 | 94 | 0.040 |
Why?
| | Europe | 1 | 2021 | 412 | 0.040 |
Why?
| | Lung Neoplasms | 1 | 2013 | 2642 | 0.040 |
Why?
| | Infusions, Intravenous | 2 | 2013 | 423 | 0.040 |
Why?
| | Microsatellite Instability | 1 | 2020 | 54 | 0.040 |
Why?
| | Translocation, Genetic | 1 | 2020 | 118 | 0.040 |
Why?
| | Brain Neoplasms | 1 | 2008 | 1322 | 0.040 |
Why?
| | Janus Kinase 2 | 1 | 2018 | 29 | 0.040 |
Why?
| | Janus Kinase 1 | 1 | 2018 | 26 | 0.040 |
Why?
| | Case-Control Studies | 1 | 2026 | 3608 | 0.030 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2018 | 109 | 0.030 |
Why?
| | DNA Methylation | 1 | 2022 | 683 | 0.030 |
Why?
| | Nitriles | 1 | 2018 | 205 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2020 | 434 | 0.030 |
Why?
| | Liver | 1 | 2026 | 1888 | 0.030 |
Why?
| | RNA | 1 | 2024 | 940 | 0.030 |
Why?
| | Mice | 1 | 2014 | 18365 | 0.030 |
Why?
| | Survival Analysis | 3 | 2008 | 1385 | 0.030 |
Why?
| | Registries | 2 | 2016 | 2385 | 0.030 |
Why?
| | Phosphoramide Mustards | 1 | 2014 | 4 | 0.030 |
Why?
| | Nitroimidazoles | 1 | 2014 | 16 | 0.030 |
Why?
| | Recurrence | 1 | 2018 | 1135 | 0.030 |
Why?
| | Drug Discovery | 1 | 2015 | 155 | 0.030 |
Why?
| | Tendons | 1 | 2015 | 129 | 0.030 |
Why?
| | Platinum Compounds | 1 | 2013 | 11 | 0.030 |
Why?
| | Research Design | 1 | 2020 | 1137 | 0.030 |
Why?
| | Crystallography, X-Ray | 1 | 2015 | 493 | 0.030 |
Why?
| | Lymphatic Metastasis | 1 | 2015 | 334 | 0.020 |
Why?
| | Dasatinib | 1 | 2013 | 57 | 0.020 |
Why?
| | Maximum Tolerated Dose | 1 | 2013 | 212 | 0.020 |
Why?
| | Palliative Care | 1 | 2002 | 1008 | 0.020 |
Why?
| | Thiazoles | 1 | 2013 | 136 | 0.020 |
Why?
| | src-Family Kinases | 1 | 2013 | 93 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2013 | 200 | 0.020 |
Why?
| | Indazoles | 1 | 2013 | 80 | 0.020 |
Why?
| | Caspase 3 | 1 | 2013 | 238 | 0.020 |
Why?
| | Canada | 1 | 2013 | 428 | 0.020 |
Why?
| | Animals | 1 | 2014 | 38109 | 0.020 |
Why?
| | Imidazoles | 1 | 2013 | 254 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2014 | 1540 | 0.020 |
Why?
| | Liver Transplantation | 1 | 2016 | 823 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2022 | 3869 | 0.020 |
Why?
| | Breast Neoplasms | 1 | 2002 | 2456 | 0.020 |
Why?
| | Southwestern United States | 1 | 2008 | 95 | 0.020 |
Why?
| | Endpoint Determination | 1 | 2009 | 83 | 0.020 |
Why?
| | Radiotherapy, Conformal | 1 | 2008 | 74 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2008 | 427 | 0.020 |
Why?
| | Exanthema | 1 | 2006 | 84 | 0.010 |
Why?
| | Blood Transfusion | 1 | 2009 | 405 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2013 | 2925 | 0.010 |
Why?
| | Combined Modality Therapy | 1 | 2008 | 1268 | 0.010 |
Why?
| | Multicenter Studies as Topic | 1 | 2005 | 405 | 0.010 |
Why?
| | Consumer Product Safety | 1 | 2002 | 32 | 0.010 |
Why?
| | Injections, Spinal | 1 | 2002 | 121 | 0.010 |
Why?
| | Delayed-Action Preparations | 1 | 2002 | 183 | 0.010 |
Why?
| | Administration, Oral | 1 | 2002 | 848 | 0.010 |
Why?
| | Quality of Life | 1 | 2008 | 3192 | 0.010 |
Why?
|
|
Cohn's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|